SCHEMBL21753573

SCHEMBL21753573

CCOC(=O)C(NNC1CC1)C(=O)Cc1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
KDM4E B2RXH2 4/20 0.39
EPHX2 P34913 1/20 0.39
PPARG P37231 1/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
POLB P06746 1/20 0.38
APEX1 P27695 1/20 0.38
SIGMAR1 Q99720 2/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 4/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
GAA P10253 2/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21753515 0.90 MEN1 (0.42) RAB9AKMT2AMEN1POLBALDH1A1
SCHEMBL21753547 0.84 SIGMAR1 (0.42) RAB9ATDP1KDM4EPOLBSIGMAR1
SCHEMBL21753522 0.79 TDP1 (0.46) RAB9ATDP1KDM4EEPHX2PPARG
SCHEMBL21753551 0.74 CHRM1 (0.36) RAB9AEPHX2PPARGKMT2AMEN1
SCHEMBL21753550 0.74 CHRM1 (0.36) RAB9AEPHX2PPARGKMT2AMEN1
SCHEMBL653111 0.73 TDP1 (0.63) RAB9ATDP1KDM4EEPHX2PPARG
SCHEMBL1287236 0.71 TDP1 (0.45) RAB9ATDP1KDM4EEPHX2PPARG
SCHEMBL16144858 0.68 TDP1 (0.51) RAB9ATDP1KDM4EKMT2AMEN1
SCHEMBL21769297 0.68 RAB9A (0.43) RAB9ATDP1KDM4EKMT2AMEN1
SCHEMBL1626240 0.67 TDP1 (0.54) RAB9ATDP1KDM4EPPARGKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3842425-B1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES NANJING INC (CN) 2024-05-22 EP disclosed
CN-110857293-B Novel quinoline derivative inhibitor 药捷安康(南京)科技股份有限公司 2023-01-10 CN disclosed
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-10 US disclosed
EP-3842425-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-06-30 EP disclosed
CN-110857293-A Novel quinoline derivative inhibitor 南京药捷安康生物科技有限公司 2020-03-03 CN disclosed
WO-2020038460-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR 南京药捷安康生物科技有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR CSF1R, CSF3R, FLT3 RAB9A 1365/4885TDP1 1719/4885KDM4E 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.